---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-26-000050"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2026-07-21T21:24:31+00:00"
generated_at: "2026-07-21T21:26:06.062273+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech discloses single-patient data from discontinued KB801 study in patent response

## Summary
- Filed response to USPTO Office Action for KB801 patent application; included data from one patient in discontinued clinical study.
- Patient experienced complete closure of persistent corneal epithelial defect after KB801 treatment.
- Study discontinued to advance KB801 into pivotal trial; no safety concerns or serious adverse events observed.
- Company cautions that single-patient observation is not top-line results and no conclusions on safety/efficacy should be drawn.
- Pivotal trial results for KB801 expected to be reported in ordinary course.

## SEC filing metadata
- accession: 0001711279-26-000050
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2026-07-21T21:24:31+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127926000050/0001711279-26-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127926000050/krys-20260721.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-26-000050
- JSON: https://secwatch.observer/filing/0001711279-26-000050.json
- Plain text: https://secwatch.observer/filing/0001711279-26-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.